samedan logo
 
 
spacer
home > pmps > winter 2020 > spotlight: dose counters and indicators – a real patient need
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Spotlight: Dose Counters and Indicators – A Real Patient Need




Asthma and chronic obstructive pulmonary diseases (COPD) are chronic lung disorders responsible for millions of deaths every year. Both diseases are characterised by variable and recurring symptoms and, when poorly controlled, can result in severe limitations in quality of life for patients. Therefore, controlling and monitoring treatments is not only a real need to reduce healthcare costs related to hospitalisations, but a real patient need. Patient expectations are towards a reliable system to support their correct and on-time use of inhalers, without changing the way of using them or adding any steps to their routine: intuitive and nondestructive, without much additional weight or form factor to carry in their daily lives.

The majority of marketed metereddose inhalers (MDIs) offer no practical way for patients or doctors to know how many doses are left in their inhaler, specifically in case of emergency. Furthermore, there is a collective requirement to track adherence or compliance to medication. To address these requirements, the FDA published guidance on integration of dosecounting mechanisms into MDI drug products. Under this guidance, devices should offer either clear numeric counting mechanisms or indication functions with colour codes or other means, leading to clear and unmistakable information to patients on drugs left in their devices. The guidance also encourages drug manufacturers to update existing devices, if possible (1-2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


H&T Presspart offers pharma customers high-precision injection moulded plastic components and deep drawn metal cans for respiratory drug delivery systems, with more than 40 years’ experience and a worldwide reputation for competence, quality, and innovation in pharma and industrial sectors. H&T Presspart Inhalation Product Technology Centre supports new product developments and strategic initiatives with its customers. Founded in 1970, and acquired by the Heitkamp and Thumann group in 2002, H&T Presspart has three European manufacturing sites in Germany, Spain, and the UK, with sales offices in China, India, South America, and the US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Grupo NotreDame Intermédica (GNDI) of Brazil enhances patient care and improves patient access to leading-edge medications by joining Clinerion’s global network of hospital partners on Patient Network Explorer

Grupo NotreDame Intermédica (GNDI) is the largest healthcare operator in Brazil, with 6.4 million members. Founded in 1968, it is a pioneer in preventive medicine. GNDI has a wide offer, comprising 29 hospitals, 88 clinical centers, 23 autonomous emergency rooms, 15 preventive medicine centers and 2 health centers exclusively dedicated to the over-fifties.
More info >>

White Papers
 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement